当前位置: 首页 >> 检索结果
共有 3491 条符合本次的查询结果, 用时 3.2379577 秒

381. Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer.

作者: Suhail Yousuf.;Mengjie Qiu.;Lena Voith von Voithenberg.;Johannes Hulkkonen.;Igor Macinkovic.;Axel R Schulz.;Domenic Hartmann.;Florian Mueller.;Margarete Mijatovic.;David Ibberson.;Karam T AlHalabi.;Jenny Hetzer.;Simon Anders.;Bernhard Brüne.;Henrik E Mei.;Charles D Imbusch.;Benedikt Brors.;Mathias Heikenwälder.;Matthias M Gaida.;Markus W Büchler.;Andreas Weigert.;Thilo Hackert.;Susanne Roth.
来源: Gastroenterology. 2023年165卷4期891-908.e14页
As pancreatic ductal adenocarcinoma (PDAC) continues to be recalcitrant to therapeutic interventions, including poor response to immunotherapy, albeit effective in other solid malignancies, a more nuanced understanding of the immune microenvironment in PDAC is urgently needed. We aimed to unveil a detailed view of the immune micromilieu in PDAC using a spatially resolved multimodal single-cell approach.

382. Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review.

作者: J C Alonso.;I Casans.;F M González.;D Fuster.;A Rodríguez.;N Sánchez.;I Oyagüez.;A O Williams.;N Espinoza.
来源: BMC Gastroenterol. 2023年23卷1期181页
Transarterial radioembolization with yttrium-90 (Y-90 TARE) microspheres therapy has demonstrated positive clinical benefits for the treatment of liver metastases from colorectal cancer (lmCRC). This study aims to conduct a systematic review of the available economic evaluations of Y-90 TARE for lmCRC.

383. Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review.

作者: Arman Shafiee.;Razman Arabzadeh Bahri.;Mohammad Mobin Teymouri Athar.;Fatemeh Afsharrezaei.;Mostafa Gholami.
来源: BMC Gastroenterol. 2023年23卷1期170页
Esophageal motility disorders are a group of disorders associated with dysfunctional swallowing resulting from impaired neuromuscular coordination. Phosphodiesterase 5 (PDE-5) inhibitors induce smooth relaxation and are proposed as a treatment option for esophageal motility disorders such as achalasia.

384. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.

作者: Lin Chang.;William D Chey.;Aamer Imdad.;Christopher V Almario.;Adil E Bharucha.;Susan Diem.;Katarina B Greer.;Brian Hanson.;Lucinda A Harris.;Cynthia Ko.;M Hassan Murad.;Amit Patel.;Eric D Shah.;Anthony J Lembo.;Shahnaz Sultan.
来源: Gastroenterology. 2023年164卷7期1086-1106页
Chronic idiopathic constipation (CIC) is a common disorder associated with significant impairment in quality of life. This clinical practice guideline, jointly developed by the American Gastroenterological Association and the American College of Gastroenterology, aims to inform clinicians and patients by providing evidence-based practice recommendations for the pharmacological treatment of CIC in adults.

385. A systematic review and meta-analysis: the therapeutic and preventive effect of Lactobacillus reuteri DSM 17,938 addition in children with diarrhea.

作者: Xiaoqi Sun.;Juan Kong.;Shuotong Zhu.;Chengjiang Liu.
来源: BMC Gastroenterol. 2023年23卷1期141页
To summarize the effect of adding Lactobacillus reuteri in the treatment plan for diarrheal disease in children, and analyze the potential of probiotics in preventing the occurrence of diarrheal disease.

386. Atrial-fibrillation-mediated cardiomyopathy: a clinical approach of catheter ablation and literature review.

作者: Lin Lu.;Daixu Li.;Guishuang Li.
来源: Minerva Gastroenterol (Torino). 2023年69卷3期451-453页

387. A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals.

作者: Kira L Newman.;Victor G Chedid.;Elisa K Boden.
来源: Gastroenterology. 2023年164卷6期866-871页

388. AGA Clinical Practice Update on Gastric Peroral Endoscopic Myotomy for Gastroparesis: Commentary.

作者: Mouen A Khashab.;Andrew Y Wang.;Qiang Cai.
来源: Gastroenterology. 2023年164卷7期1329-1335.e1页
The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to review the available evidence and provide expert advice regarding cognitive, procedural, and post-procedural aspects of performing gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis.

389. Defining Interactions Between the Genome, Epigenome, and the Environment in Inflammatory Bowel Disease: Progress and Prospects.

作者: Alexandra J Noble.;Jan K Nowak.;Alex T Adams.;Holm H Uhlig.;Jack Satsangi.
来源: Gastroenterology. 2023年165卷1期44-60.e2页
Recent advances in our understanding of the pathogenesis of inflammatory bowel disease (IBD) have highlighted the complex interplay between the genome, the epigenome, and the environment. Despite the exciting advances in genomics that have enabled the identification of over 200 susceptibility loci, these only account for a small proportion of the disease variance and the estimated heritability in IBD. It is likely that gene-environment (GxE) interactions contribute to "missing heritability" and these may act through epigenetic mechanisms. Several environmental factors, such as the microbiome, nutrition, and tobacco smoking, induce alterations in the epigenome of children and adults, which may impact disease susceptibility. Other mechanisms for GxE interactions are also directly pertinent in early life. We discuss a model in which environmental factors imprint disease risk in a window of susceptibility during infancy that may contribute to later disease onset, whereas other elements of the exposome act later in life and contribute directly to the pathogenesis and course of the disease. Understanding the mechanisms underlying GxE interactions may provide the basis for new therapeutic targets or preventative strategies for IBD.

390. Repeatability of radiomics studies in colorectal cancer: a systematic review.

作者: Ying Liu.;Xiaoqin Wei.;Xu Feng.;Yan Liu.;Guiling Feng.;Yong Du.
来源: BMC Gastroenterol. 2023年23卷1期125页
Recently, radiomics has been widely used in colorectal cancer, but many variable factors affect the repeatability of radiomics research. This review aims to analyze the repeatability of radiomics studies in colorectal cancer and to evaluate the current status of radiomics in the field of colorectal cancer.

391. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

作者: Zijiao Yang.;Xia Jiang.
来源: BMC Gastroenterol. 2023年23卷1期122页
Currently, surgical resection is the most commonly performed and effective treatment for intrahepatic cholangiocarcinoma (ICC) worldwide. However, the prognosis of ICC is unsatisfactory. This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy followed by surgery and upfront surgery in treating intrahepatic cholangiocarcinoma (ICC). The study also intends to explore whether chemotherapy should be introduced before surgery and which populations should be considered for neoadjuvant chemotherapy.

392. Thiols as a marker of inflammatory bowel disease activity: a systematic review.

作者: Rebeca Araujo Passos.;Priscila Ribas Farias Costa.;Claudia Feio da Maia Lima.;George Mariane Soares Santana.;Victor David.;Geisa de Jesus Santos.;Cyrla Zaltman.;Marcia Soares-Mota.;Raquel Rocha.
来源: BMC Gastroenterol. 2023年23卷1期94页
Evidence indicates that inflammation in Inflammatory Bowel Disease (IBD) is associated with increased systemic levels of reactive oxygen species. Systemic oxidative stress has been associated with reduced levels of plasma thiols. Less invasive tests capable of reflecting and predicting IBD activity are increasingly sought after. We sought to systematically review the evidence inherent in serum thiol levels as a marker of Crohn's Disease and Ulcerative Colitis activity (PROSPERO: CRD42021255521).

393. Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis.

作者: Xu Zhang.;Li-Na Wu.;Xiao-Qing Li.;Xia Luo.;Shui-Wei Liu.;Le Zhang.;Shah Nawaz.;Li-Na Ma.;Xiang-Chun Ding.
来源: BMC Gastroenterol. 2023年23卷1期85页
The Value of Golgi protein 73 (GP73) in the diagnosis of Hepatocellular carcinoma (HCC) remains controversial, especially in its differentiation between HCC and cirrhosis. Besides, some papers showed that GP73 levels are correlated with liver fibrosis. This study conducts a meta-analysis to evaluate the value of GP73 in diagnosing HCC and differential diagnosing HCC from liver cirrhosis.

394. Association between intestinal microflora and obesity.

作者: Maryana Savytska.;Marko Kozyk.;Kateryna Strubchevska.;Kateryna Yosypenko.;Tetyana Falalyeyeva.;Nazarii Kobyliak.;Luigi Boccuto.;Rinaldo Pellicano.;Sharmila Fagoonee.;Emidio Scarpellini.;Ludovico Abenavoli.
来源: Minerva Gastroenterol (Torino). 2024年70卷3期342-352页
Obesity has become one of modern society's most serious health problems. Studies from the last 30 years revealed a direct relationship between imbalanced energy intake and increased healthcare costs related to the treatment or management of obesity. Recent research has highlighted significant effects of gut microbial composition on obesity. We aimed to report the current knowledge on the definition, composition, and functions of intestinal microbiota. We have performed an extensive review of the literature searching for the following key words: metabolism, gut microbiota, dysbiosis, and obesity. There is evidence that an association between intestinal microbiota and obesity exists at any age. There are complex genetic, metabolic, and inflammatory mechanisms involved in the pathogenesis of obesity. Revision of indications for use of probiotics, prebiotics, and antibiotics in obese patients should be considered. Microbial composition of the gut may be an important factor involved in the development of obesity. Changes in the gut microbiota may result in changes in human metabolism and weight loss.

395. Sorghum (Sorghum vulgare): an ancient grain, a novel choice for a healthy gluten-free diet.

作者: Tommaso Dionisi.;Emanuele Rinninella.;Pauline Raoul.;Marco Cintoni.;Maria C Mele.;Gabriele Gasbarrini.;Rinaldo Pellicano.;Gabriele A Vassallo.;Antonio Gasbarrini.;Giovanni Addolorato.;Giovanni B Gasbarrini.
来源: Minerva Gastroenterol (Torino). 2024年70卷2期231-241页
Celiac disease (CD) is an autoimmune disease related to gluten consumption. To date, the only effective therapy that can reverse symptoms and prevent complications is the gluten-free diet (GFD), which is challenging to maintain and has potential health risks. Identifying foods that can help diversify the GFD and that best match the nutritional needs of people with CD may improve the health and quality of life of celiac patients. This review, conducted through a non-systematic search of the available literature, aims to gather the most recent research on nutritional issues in CD and GFD. Moreover, it highlights how sorghum characteristics could provide health benefits to CD patients that counteract the nutritional problems due to CD and the nutritional consequences of GFD acceptance. Sorghum contains a wide variety of bioactive compounds, such as flavones and tannins, that have shown anti-inflammatory activity in preclinical studies. They can also regulate blood sugar levels and lower cholesterol to reduce the effects of common chronic diseases such as metabolic and cardiovascular diseases. Because it is gluten-free, its use in making foods for celiac patients is increasing, especially in the United States. In conclusion, sorghum is a fascinating grain with nutritional properties and health benefits for supplementing GFD. However, only one study confirms the short-term safety of sorghum inclusion in the GFD, and further long-term studies with a large sample are needed.

396. Systematic review of cholangiocarcinoma in Africa: epidemiology, management, and clinical outcomes.

作者: Akwi W Asombang.;Nathaniel Chishinga.;Mouhand F Mohamed.;Alick Nkhoma.;Jackson Chipaila.;Bright Nsokolo.;Martha Manda-Mapalo.;Joao Filipe G Montiero.;Lewis Banda.;Kulwinder S Dua.
来源: BMC Gastroenterol. 2023年23卷1期66页
The prevalence, management, and clinical outcomes of cholangiocarcinoma in Africa are unknown. The aim is to conduct a comprehensive systematic review on the epidemiology, management, and outcomes of cholangiocarcinoma in Africa.

397. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.

作者: Gabriele Castelnuovo.;Nuria Perez-Diaz-Del-Campo.;Marta Guariglia.;Irene Poggiolini.;Angelo Armandi.;Chiara Rosso.;Gian P Caviglia.;Elisabetta Bugianesi.
来源: Minerva Gastroenterol (Torino). 2024年70卷4期446-453页
Non-alcoholic steatohepatitis (NASH) is a high-prevalence, rapidly growing form of non-alcoholic fatty liver disease (NAFLD), which is closely linked to obesity and metabolic disorders. Gut microbiota has been increasingly recognized as a key factor in the onset of NAFLD in recent years. The liver can be strongly influenced by changes in the gut microbiota through the portal vein, giving the gut-liver axis a very important role in understanding the pathophysiology of liver diseases. A healthy intestinal barrier is characterized by selective permeability to nutrients, metabolites, water and bacterial products and its impairment may be a predisposing or aggravating condition for the progression of NAFLD. In most cases, NAFLD patients follow a Western diet pattern, which is closely linked to obesity and associated metabolic diseases, promoting inflammation, structural and behavioral changes in the gut microbiota. In fact, factors such as age, gender, genetic or environmental factors may induce a dysbiotic microbiota that promotes epithelial barrier dysfunction and increased intestinal permeability, favoring the progression of NAFLD. In this context, new dietary approaches, such as prebiotics, are emerging to prevent disease and maintain health. In this review, we reported the role of the gut-liver axis in the pathogenesis of NAFLD and investigated the potential therapeutic effect of prebiotics on the enhancement of intestinal barrier dysfunction, hepatic steatosis and, consequently, the progression of NAFLD.

398. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.

作者: Sintayehu Fekadu.;Hizkel Engiso.;Sisay Seyfe.;Hisashi Iizasa.;Ashebir Godebo.;Serawit Deyno.;Hironori Yoshiyama.
来源: BMC Gastroenterol. 2023年23卷1期55页
The effectiveness of Helicobacter pylori (H. pylori) eradication depends on the treatment protocol. This study investigates the H. pylori eradication rate in Africa using the best available evidence from databases.

399. Health-related quality of life and symptoms in autoimmune liver diseases.

作者: Maciej K Janik.;Ewa Wunsch.;Piotr Milkiewicz.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期50-60页
Assessment of Health-Related Quality of Life (HRQoL) has emerged as an important tool in the evaluation of both the well-being of patients and the results of their clinical management. Over the years, a large number of questionnaires focusing on various aspects of quality of life have been developed. They are frequently divided into generic questionnaires, which can be used under various conditions, disease-specific and symptom-specific questionnaires. Autoimmune liver diseases, such as autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis, comprise a group of rare liver conditions (i.e. affecting fewer than 5 in 10,000 people in the general population). Unfortunately, HRQoL has not been well-studied in this group of patients. In this review, we comprehensively summarize the data available in the literature on HRQoL in these conditions, emphasizing the important role that quality of life plays in the successful management of such patients.

400. Colorectal Cancer Risk Assessment and Precision Approaches to Screening: Brave New World or Worlds Apart?

作者: Fay Kastrinos.;Sonia S Kupfer.;Samir Gupta.
来源: Gastroenterology. 2023年164卷5期812-827页
Current colorectal cancer (CRC) screening recommendations take a "one-size-fits-all" approach using age as the major criterion to initiate screening. Precision screening that incorporates factors beyond age to risk stratify individuals could improve on current approaches and optimally use available resources with benefits for patients, providers, and health care systems. Prediction models could identify high-risk groups who would benefit from more intensive screening, while low-risk groups could be recommended less intensive screening incorporating noninvasive screening modalities. In addition to age, prediction models incorporate well-established risk factors such as genetics (eg, family CRC history, germline, and polygenic risk scores), lifestyle (eg, smoking, alcohol, diet, and physical inactivity), sex, and race and ethnicity among others. Although several risk prediction models have been validated, few have been systematically studied for risk-adapted population CRC screening. In order to envisage clinical implementation of precision screening in the future, it will be critical to develop reliable and accurate prediction models that apply to all individuals in a population; prospectively study risk-adapted CRC screening on the population level; garner acceptance from patients and providers; and assess feasibility, resources, cost, and cost-effectiveness of these new paradigms. This review evaluates the current state of risk prediction modeling and provides a roadmap for future implementation of precision CRC screening.
共有 3491 条符合本次的查询结果, 用时 3.2379577 秒